Steven Cohen Morpho Sys Ag Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $16.5 Million - $35.9 Million	3,628,028 Added 2075.32%	3,802,846 $37.6 Million
Q3 2023 Nov 14, 2023	SELL	$6.72 - $8.6 $294,887 - $377,385	-43,882 Reduced 20.06%	174,818 $1.17 Million
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $863,865 - $1.69 Million	218,700 New	218,700 $1.63 Million
Q1 2019 May 15, 2019	SELL	$22.55 - $29.84 $4.51 Million - $5.97 Million	-200,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$21.96 - $31.02 $4.39 Million - $6.2 Million	200,000 New	200,000 $5.06 Million

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.